PDI signs four-year deal with Novartis

Share this article:
Contract sales firm PDI signed a four-year agreement with Novartis to deploy a field force promoting Elidel, a second-line eczema treatment for patients older than 2 years, according to Kim Golodetz, a spokesperson for PDI. 

The deal calls for deployment of “approximately 100 full-time equivalent sales representatives who will call upon physicians nationwide,” a PDI statement said. 

After losing contracts with GlaxoSmithKline and Sanofi-Aventis in 2006, PDI rebounded with a “top-five pharmaceutical company” contract in 2007.  

In February, the company named Peter Tilles president of its TVG marketing research and consulting unit.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions